Pinned Tweet
1/ There was a different COVID vaccine all along. Here's the paper trail on how it got held back.
Novavax's Nuvaxovid is a traditional protein vaccine, the same platform family as the hepatitis B shot. In a roughly 30,000-person trial against a saline placebo: 90.4% efficacy. No mRNA. No lipid nanoparticles. In a UK randomized trial, its side effects ran milder than the mRNA shots.
nih.gov/news-events/news-rel…
Here's a thought for $NVAX and $PFE holders that the market isn't pricing in.
In January, $PFE paid @Novavax $30M upfront for a non-exclusive license to use Matrix-M in up to two infectious diseases. Pfizer has already picked the first one, and neither company will say which. Each disease can earn $NVAX up to $70M in development milestones and $180M in sales milestones, plus high mid-single-digit royalties on sales.
In February, a Novavax patent application went public: "Pneumococcal Conjugate Vaccines with Saponin-Based Adjuvants." They added Matrix-M to off-the-shelf Prevnar 13. In mice, antibody titers were 7.6x higher after two doses and 8.3x higher after three, with better bacterial killing across serotypes. Novavax's own investor deck says that could mean a more potent vaccine that needs less antigen per dose.
Now look at where @pfizer is going:
- The Prevnar family did $6.49B in 2025. It's $PFE's biggest vaccine and its No. 2 product overall.
- Pfizer skipped ahead to a 35-valent adult Prevnar. It's due to enter the clinic by the end of 2026 and promises "next-generation technology" to boost serotype 3, which has always been the weak spot.
- @Merck's $MRK Capvaxive (21-valent) is already competing for adults, and @Vaxcyte's $PCVX 31-valent VAX-31 just hit its Phase 3 endpoints, with a filing targeted for early 2028.
- Older Prevnar patents are starting to roll off. $PFE needs a new moat.
The catch with 35 serotypes is that every one adds polysaccharide and carrier protein to the same shot. The more you pack in, the harder it is to get a strong response to each serotype. An adjuvant that does more with less antigen solves exactly that problem.
What it could do for $PFE:
- Dose sparing: less antigen per serotype, which lowers cost of goods and leaves room to add serotypes.
- Stronger responses on the hard serotypes, like 3.
- An edge $MRK and $PCVX can't match on serotype count alone. When everyone is racing on breadth, you win on response quality.
- A new formulation with its own data and IP as the older patents expire.
What it could do for $NVAX: do the napkin math. A royalty of about 6% on a $6.5B franchise is roughly $390M a year, before milestones and adjuvant supply. Even a slice of that is recurring revenue that doesn't depend on one COVID season.
To be fair, nobody has confirmed pneumococcal is the field. Pfizer hasn't said, the 35-valent hasn't started trials, and it would take years. But $PFE paid cash for the license, Novavax's own patent shows Matrix-M working with Prevnar, and Pfizer's next Prevnar needs exactly what Matrix-M does. That's a lot of dots lining up.
The same Matrix-M adjuvant is in a vaccine you can get right now: Nuvaxovid, the protein-based COVID shot from @Novavax and @sanofi. In April, the randomized, double-blind COMPARE trial of 1,000 US adults ran it head-to-head against @moderna_tx's newest mRNA shot, mNEXSPIKE:
- Moderate-to-severe body-wide side effects: 43% with Nuvaxovid vs 61% with mNEXSPIKE
- Moderate-to-severe arm reactions: 39% vs 59%
- Side effects bad enough to stop normal daily activities: under 1 in 10 vs 1 in 5
- People who'd definitely pick the same shot next year: 30% vs 16%
If Pfizer thinks Matrix-M is good enough for its crown jewel, it only makes sense that other pharmas will too. And don't forget the potential cancer applications.
$NVAX $PFE $MRK $PCVX $SNY $MRNA
1
2
62
On the cancer point: this isn't just hope. Novavax's Q2 2026 deck has a slide called "Why Oncology, Why Now: Matrix-M Opportunity," and at @Jefferies on Nov 17, management said internal preclinical cancer work came back very positive. The focus is durable CD8 T-cell responses, which is what therapeutic cancer vaccines need. They have an MTA with a top-10 pharma in oncology, and the next tranche of data is expected by early 2027. $NVAX
11
Tim M retweeted
Replying to @TJMeehan1 @DrTrozzi
Tim, I think you'll like this one. We should name it the TimM video...
12/ Meanwhile, Blackstone committed up to $750M to Moderna's mRNA flu program in 2024. FDA approved Moderna's mRNA flu shot on Aug 5, 2026. And on Sept 23, 2026, the Pentagon (now the Department of War) awarded Flagship a contract worth up to $47M over five years for countermeasure technology.
blackstone.com/news/press/bl…
fda.gov/media/194121/downloa…
fiercebiotech.com/biotech/de…
1
24
13/ Two asks.
@RobertKennedyJr: reinstate the placebo-controlled studies FDA dropped in August. Science needs a fair fight and a real answer.
And if you're 65+, or 12-64 with a high-risk condition, ask your doctor or pharmacist for Nuvaxovid by name. FDA approved its 2026-27 formula on Aug 27. Protein, not instructions.
1
30
Novavax is the biggest untold scandal of the pandemic, and the receipts are public. I laid them out for @USAWatchdog: the trial data, the approval delay, Sweden choosing protein over mRNA, and the money trail. Credit to @CamillusLellis and @colorfuzion_web for digging. Read it and decide for yourself.
Replying to @USAWatchdog
Greg, the clot story and the Novavax story are two halves of the same scandal, and Novavax is the biggest untold scandal of the pandemic. A protein vaccine, the same proven approach behind the hepatitis B and HPV shots, delivered a measured dose with no lipid nanoparticles and no genetic instructions. In a 30,000-person trial against a true saltwater placebo, it showed 90.4% efficacy, 100% against moderate-to-severe disease, and zero hospitalizations in the vaccine arm. Yet it was authorized 19 months after Pfizer, after the mandates had already done their work, then under-ordered and buried under mRNA's warnings. Someone with your reach could pull this thread. Here's where to start.
PREVENT-19 trial, NEJM:
nejm.org/doi/full/10.1056/NE…
FDA Nuvaxovid page:
fda.gov/vaccines-blood-biolo…
Sweden ran its own national tender for 2027/28. Nuvaxovid beat both Pfizer and Moderna, and Sweden became the first country to buy only a protein-based COVID vaccine:
lakemedelsmarknaden.di.se/sa…
@colorfuzion_web broke it down here:
Was it late, or kept waiting? The trial data and the 1,362-day approval gap:
teapawt.net/TJMeehan1/status/21223…
Follow the royalties: why the system favors one platform:
teapawt.net/TJMeehan1/status/21171…
@CamillusLellis on the scandal itself:
teapawt.net/CamillusLellis/status/…
Camillus on the executive stock sales, the $1.6B in Warp Speed money, and the short-selling collapse:
teapawt.net/CamillusLellis/status/…
The question mainstream media won't ask: if a safer option existed all along, why was it held back while millions were mandated into mRNA? The receipts are public. Worth a deep dive.
teapawt.net/colorfuzion_web/status…
1
3
133
For anyone who wants to go deeper, here are the receipts, in order.
1. There was a safer option all along. The short version:
2. Was it late, or kept waiting? A 30,000-person saltwater placebo trial, 90.4% efficacy, zero hospitalizations, and still 1,362 days behind Pfizer for full approval:
teapawt.net/TJMeehan1/status/21223…
3. The math they use to wave it off actually makes the case for it:
teapawt.net/TJMeehan1/status/21229…
4. What's in the vial. A fixed dose of finished protein. Your cells are given nothing to build:
teapawt.net/TJMeehan1/status/21151…
5. What the FDA knew. Monkey studies, nasal clearance, and the questions nobody followed up:
teapawt.net/TJMeehan1/status/21173…
6. DNA inside lipid nanoparticles. They had to have known:
teapawt.net/TJMeehan1/status/21163…
7. The one trial that would have settled it. A placebo-controlled spike study, protein vs mRNA, ordered by Prasad and quietly cancelled after he left:
teapawt.net/TJMeehan1/status/21148…
8. Then Pfizer got to design its own version:
teapawt.net/TJMeehan1/status/21148…
9. Why Prasad was driven out:
teapawt.net/TJMeehan1/status/21199…
10. What happened next. The mRNA flu shot got pushed through anyway:
teapawt.net/TJMeehan1/status/21202…
11. Follow the royalties. Every mRNA dose pays universities, NIH, and the makers. The protein shot pays none of them:
teapawt.net/TJMeehan1/status/21171…
12. Meanwhile the stock gets shorted and the headlines recycle old news:
teapawt.net/TJMeehan1/status/21149…
Same disease. Different technology. Different treatment. Read it all and ask why nobody is telling this story.
teapawt.net/TJMeehan1/status/21122…
Replying to @DrAseemMalhotra
@DrAseemMalhotra Dr. Malhotra, you’re right: industry incentives over patient outcomes. Here is the COVID vaccine story that proves it. Feel free to use it.
1/ There was a safer option all along. Novavax/Nuvaxovid is a traditional protein COVID vaccine: 90.4% efficacy against a saline placebo. No mRNA, no lipid nanoparticles, no genetic code telling your cells to make spike. In primates, just 5 µg cleared virus from the upper and lower airways.
2/ FDA to Pfizer. Scott Gottlieb ran the FDA while Novavax’s protein platform proved itself. Two months after leaving in 2019, he joined Pfizer’s board. Then he was on CNBC as an “independent expert” pushing boosters without disclosure, and the Twitter Files show he pressured Twitter over mRNA critics.
3/ FDA to Moderna’s creator. Stephen Hahn was FDA commissioner when Moderna got its EUA. He left Jan 20, 2021, and Flagship Pioneering, the firm that created Moderna and whose founder still chairs Moderna’s board, made him chief medical officer on June 16, 2021.
4/ Fauci’s lab to Penn. Drew Weissman trained in Fauci’s NIAID lab (1990–93), then was NIAID senior staff (1993–97), then went to Penn. Weissman and Karikó got about $2.3M from NIAID for the core mRNA papers. Weissman alone got 42 NIH awards worth about $18.3M. Federal grants sit on the patents.
5/ The royalty machine. BioNTech paid Penn about $1.6B in 2021–23, plus a settlement of up to $467M. NIH took $791.5M from BioNTech and $400M from Moderna, and government inventors get a personal cut of up to $150K a year. Novavax paid NIH $0.
6/ The media. Pfizer’s board also had James C. Smith, ex-CEO of Thomson Reuters and chair of the Thomson Reuters Foundation. In 2021–22 Reuters ran about 1,200 Pfizer stories and about 120 on Novavax, more than 70% negative. Pfizer spent $2.8B on ads in 2022.
7/ The regulators. Peter Marks at CBER, which was Fauci and Marks’ “crowning achievement” mRNA program, demanded 95%+ purity from Novavax when protein vaccines were historically approved at about 80–85%. The FDA’s chosen partner, Emergent, contaminated batches. Result: an 18-month delay while mRNA took the market.
8/ The money keeps flowing. Blackstone Life Sciences committed up to $750M to Moderna’s mRNA flu program. On Sept 23, 2026, the Pentagon gave Flagship a biodefense contract.
9/ The cover-up continues. Prasad mandated a post-marketing placebo RCT on spike in the blood after COVID shots, protein vs mRNA. Right after he left, it was canceled. A head-to-head would make cash-cow mRNA look terrible.
Science needs disagreement, and a fair fight. @RobertKennedyJr, reinstate the RCT.
1
36
Novavax is the biggest untold scandal of the pandemic, and the receipts are public. I laid them out for @USAWatchdog: the trial data, the approval delay, Sweden choosing protein over mRNA, and the money trail. Credit to @CamillusLellis and @colorfuzion_web for digging. Read it and decide for yourself.
This quoted post is unavailable.
1
44
"Less than 1% absolute risk reduction" is the line they use to wave off every vaccine. So I ran the math on the protein one. Short trial, a lull in cases, and still a 90% reduction, with zero moderate-to-severe cases and zero hospitalizations. When the benefit is that close between shots, the risk side decides it. If you're 65 or older or have a health condition, ask for Nuvaxovid by name.
Replying to @DrTrozzi
Thanks Dr. Trozzi. Run the ARR math, because it's the case for the protein shot. PREVENT-19 had 14 cases in about 17,300 vaccinated people (0.08%) and 63 in about 8,100 on saltwater placebo (0.77%). That's a 90% relative reduction and an ARR of 0.69%. ARR looks small because the trial ran only about 3 months during a lull. It tells you how much virus was going around, not what's in the vial. Apply that same 90% to a winter wave where 10 to 20% of people get infected, and you prevent roughly 1 infection for every 6 to 11 people vaccinated. The severe numbers matter more: zero moderate-to-severe cases and zero hospitalizations in the vaccine arm. Your point does hold in one way. When the benefit in any given window is modest, the risk side decides it, and that's where the platform matters. Pfizer's ARR was 0.84%, about the same, but they unblinded their placebo arm within months, so there's no long-term controlled safety comparison. The protein shot gives similar protection from a measured dose your body clears, with no LNPs and no genetic instructions that keep running. Millions were pushed into taking something to keep a job, see a parent in a nursing home, or travel. The one option with a clean risk profile was delayed, under-ordered, and saddled with mRNA's warnings. That wasn't informed consent. It was a rigged menu. But the menu is open now. If you're 65 or older, or you have a health condition, and winter is coming, you can walk into a pharmacy and ask for Nuvaxovid by name. Same protection, none of the mRNA baggage. Don't let them hand you "the COVID vaccine." Ask for the protein one.
3
52


